FindTrial
Sign In

Efficacy and safety evaluation of Danhong injection in perioperative period of myocardial infarction during PCI: a retrospective cohort study

Efficacy and safety evaluation of Danhong injection in perioperative period of myocardial infarction during PCI: a retrospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053213
Enrollment
Unknown
Registered
2021-11-15
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction

Interventions

Danhong injection group:Nil
Conventional western medicine treatment group:Nil

Sponsors

Jiangxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for MI and undergo PCI; 2. Aged >= 18 and < 75 years, no gender limit.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating patients; 2. Those with bleeding tendency; 3. Incomplete medical record information, such as lack of outcome and follow-up records; 4. Participate in other clinical investigators at the same time.

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular events;Non-reflow rate;—

Secondary

MeasureTime frame
Left ventricular ejection fraction;Creatine kinase isoenzyme;Cardiac troponin;C-reactive protein;—

Countries

China

Contacts

Public ContactChen Xiaofan

Jiangxi University of Chinese Medicine

xiaofanci122306@163.com+86 18507915566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026